Levetiracetam + Carbamazepine + Lamotrigine
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Focal Epilepsy
Conditions
Focal Epilepsy
Trial Timeline
Jan 1, 2007 → Aug 1, 2011
NCT ID
NCT00438451About Levetiracetam + Carbamazepine + Lamotrigine
Levetiracetam + Carbamazepine + Lamotrigine is a approved stage product being developed by UCB for Focal Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT00438451. Target conditions include Focal Epilepsy.
What happened to similar drugs?
3 of 9 similar drugs in Focal Epilepsy were approved
Approved (3) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00438451 | Approved | Completed |
Competing Products
20 competing products in Focal Epilepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OnabotulinumtoxinA 145 UNT [Botox] | AbbVie | Approved | 35 |
| Dapagliflozin | AstraZeneca | Approved | 43 |
| Enfuvirtide + Tenofovir-Emtricitabine | Roche | Phase 2 | 35 |
| CCX140-B | Amgen | Phase 2 | 27 |
| PF-06730512 | Pfizer | Phase 2 | 27 |
| Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide | Pfizer | Approved | 43 |
| VX-147 | Vertex Pharmaceuticals | Phase 2 | 35 |
| VX-147 | Vertex Pharmaceuticals | Phase 1 | 29 |
| IXP | Vertex Pharmaceuticals | Phase 1 | 29 |
| fresolimumab + fresolimumab + Placebo | Sanofi | Phase 2 | 35 |
| GC1008 + GC1008 + GC1008 + GC1008 | Sanofi | Phase 1 | 29 |
| frexalimab + brivekimig + rilzabrutinib + placebo | Sanofi | Phase 2 | 42 |
| Vivaglobin | CSL | Phase 2 | 35 |
| UCB0942 | UCB | Phase 2 | 27 |
| Brivaracetam + Brivaracetam | UCB | Phase 2 | 35 |
| Lacosamide | UCB | Phase 2 | 27 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 35 |
| Lacosamide | UCB | Pre-clinical | 26 |
| ARGX-117 | Argenx | Phase 2 | 36 |
| Empasiprubart + IVIG (Intravenous Immunoglobulin) | Argenx | Phase 3 | 44 |